A Softer View of Drug Addiction

by Michael Nguyen, PharmD, CPh
Director of Clinical Pharmacy

Michael Nguyen

In a first report of its kind, the Office of the Surgeon General is providing a framework for addressing America’s crippling alcohol and drug addiction problem. The 428-page report, Facing Addiction in America: The Surgeon General’s Report on Alcohol, Drugs, and Health, contains a chapter on neurobiology, which compares alcohol and substance addiction to other …

It’s a Partnership with our Clients – Patient Advocacy is our Top Priority

by Devin Motley
Regulatory Counsel

The United States Department of Labor released a study October 5, 2016 entitled “Does the workers’ compensation system fulfill its obligations to injured workers?” A full copy of the report can be found here. The release of the report was accompanied by a webinar co-sponsored by the National Academy of Social Insurance, and included speakers …

FDA Black Box Warnings for Combined Opioid and Benzodiazepine Use

by Michael Nguyen, PharmD, CPh, Director of Clinical Services
Andi Moore, PharmD

Michael Nguyen

After an extensive review of the latest scientific evidence, the U.S. Food and Drug Administration announced on August 31, 2016, that class-wide changes to drug labeling, including patient information, was being required for the opioid and benzodiazepine therapeutic classes because of serious risks associated with using medications from these two classes at the same time. …

Aging and Opioids: 
Important Considerations in Drug Selection

by Phil Walls, RPh
Chief Clinical Officer

Approximately 10,000 baby boomers will turn 65 every day until about the year 2030, according to the U.S. Census Bureau, and last year about one-fifth of all employed workers were age 55 or older. In addition to the challenges this aging workforce may pose for employers, this patient population may also have a significant impact …

Evzio’s 400% Price Spike

by Michael Nguyen
PharmD, CPh, Director of Clinical Services

Michael Nguyen

Despite an ongoing opioid epidemic, the newest drug designed to reverse an overdose has spiked in price.  Evzio® first became available in July 2014 for $690 per kit (AWP).  Since then, the manufacturer, Kaléo, has raised the price twice–first in November 2015 to $900 and again in February 2016 to $4500.  That is an astonishing …

The Office of Inspector General Weighs In on Opioids and Compounds

by Phil Walls, RPh
Chief Clinical Officer

Both opioid and compound drug overuse and expense have long been a significant concern in workers’ compensation. More recently, national attention has focused on the prescription drug abuse epidemic, especially as it relates to opioid overuse, abuse, addiction and death. The opioid epidemic prompted the Centers for Disease Control and Prevention (CDC) to publish a …

Epclusa® Approved for Chronic Hepatitis C

by Sam Aminov
PharmD, MBA

The U.S. Food and Drug Administration has approved Epclusa to treat adult patients with chronic hepatitis C virus (HCV) both with and without cirrhosis. Epclusa is a fixed-dose combination tablet containing sofosbuvir and velpatasvir, and it is the first drug to  treat all six major forms of HCV. Epclusa has been proven to be highly effective. …

Buyer Beware!

by Michael Nguyen, PharmD, CPh, Director of Clinical Services
Phil Walls, RPh, Chief Clinical Officer

Michael Nguyen

PatchWerx Alert If you haven’t heard of PatchWerx yet, please be on the alert for the following products from this manufacturer: In this age of life-saving specialty drugs that cost upwards of $1000 a day, one might think that PatchWerx Labs falls into this category of specialty drug manufacturers.  However, that is not the case! …